Search by Drug Name, NDC or Jcode
Internal Navigation
HCPCS Details
HCPC | J0896 |
Short Description | Inj luspatercept-aamt 0.25mg |
Long Description | Injection, luspatercept-aamt, 0.25 mg |
Pricing indicator | 51 |
Coverage code | C |
ASC payment group code | YY |
BETOS2 code | O1E |
Action code | N |
Type of service | 1 |
Effective date | 2020-07-01 |
Date Added | 2020-07-01 |
HCPCS/NDC Cross-Walk
NDC | HCPC | Description | Drug Name | Labeler Name | HCPCS Dosage | PKG Size | PKG QTY | Bill Units | Bill Units PKG |
---|---|---|---|---|---|---|---|---|---|
59572071101 | J0896 | Inj luspatercept-aamt 0.25mg | Reblozyl | CELGENE CORPORATION | 0.25 MG | 1 | 1 | 100 | 100 |
59572077501 | J0896 | Inj luspatercept-aamt 0.25mg | Reblozyl | CELGENE CORPORATION | 0.25 MG | 1 | 1 | 300 | 300 |
Drug Details
-
Luspatercept-aamt injection is used to treat anemia (a lower than normal number of red blood cells) in adults who are receiving blood transfusions to treat thalassemia (an inherited condition that causes a low number of red blood cells). Luspatercept-aamt injection is also used to treat anemia in adults with certain types of myelodysplastic syndrome (a group of conditions in which the bone marrow produces blood cells that are misshapen and does not produce enough healthy blood cells) and who are receiving blood transfusions, but have not responded to or cannot receive treatment with an erythropoiesis-stimulating agent (ESA). Luspatercept-aamt is in a class of medications called erythroid maturation agents. It works by increasing the number and quality of red blood cells.